NPS Pharmaceuticals to Present at Barclays Capital Global Healthcare Conference Barclays Capital Global Healthcare Conference Business Wire BEDMINSTER, N.J. -- March 5, 2013 NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) will present at the Barclays Capital Global Healthcare Conference in Miami, Florida on Wednesday, March 13, 2013 at 11:15 a.m. ET. The presentation will be available as a live webcast with a replay available approximately three hours after the presentation has concluded. Interested parties may access the webcast from the investors’ calendar of events page on the NPS website at http://www.npsp.com/calendar. About NPS Pharmaceuticals NPS Pharmaceuticals is a biopharmaceutical company pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide. The company’s lead product, Gattex® 0.05 mg/kg/d (teduglutide [rDNA origin]) for injection is FDA-approved for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. NPS is also developing Natpara® (rhPTH[1-84]) for the treatment of adult hypoparathyroidism and expects to submit its Biologic License Application (BLA) to the FDA in 2013. NPS's earlier stage pipeline includes two calcilytic compounds, NPSP790 and NPSP795, with potential application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia with hypercalciuria (ADHH). NPS complements its proprietary programs with a royalty-based portfolio of products and product candidates that includes agreements with Amgen, GlaxoSmithKline, Janssen Pharmaceuticals, Kyowa Hakko Kirin, and Takeda GmbH. Contact: NPS Pharmaceuticals, Inc. Gail Brophy, 908-450-5335
NPS Pharmaceuticals to Present at Barclays Capital Global Healthcare Conference
Press spacebar to pause and continue. Press esc to stop.